Celecoxib inhibits meningioma tumor growth in a mouse xenograft model

Cancer

Volumn 109, Issue 3, 2007, Pages 588-597

  Ragel, Brian T ^a,b   Jensen, Randy L ^a,b   Gillespie, David L ^b   Prescott, Stephen M ^b   Couldwell, William T ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Celecoxib; COX 2; Cyclooxygenase 2; In vivo; Meningioma

Indexed keywords

BLOOD CLOTTING FACTOR 8; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; KI 67 ANTIGEN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MEGADOSE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MENINGIOMA; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; FACTOR VIII; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; PYRAZOLES; SULFONAMIDES; SURVIVAL RATE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33846700069     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22441     Document Type: Article

References (46)

1. Burger PC, Scheithauer BW, Vogel FS, eds. Surgical Pathology of the Nervous System and Its Coverings, 4th ed. Philadelphia: Churchill Livingstone; 2002.
2. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System. Lyon: IARC Press; 2000.
3. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psych. 1957;20:22-39.
4. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression after neurosurgical resection. J Neurosurg. 1985;62:18-24.
5. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233-242.
6. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys. 1996;34:817-822.
7. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9:156-158.
8. Barnett GH, Suh JH, Crownover RL. Recent advances in the treatment of skull base tumors using radiation. Neurosurg Clin N Am. 2000;11:587-596.
9. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids. 2000;65:795-800.
10. Phillips LE, Koepsell TD, van Belle G, Kukull WA, Gehrels JA, Longstreth WT Jr. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology. 2002;58:1849-1852.
11. Kunz T, Marklund N, Hillered L, Oliw EH. Cyclooxygenase-2, prostaglandin synthases, and prostaglandin H2 metabolism in traumatic brain injury in the rat. J Neurotrauma. 2002;19:1051-1064.
12. Prescott SM. Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest. 2000;105:1511-1513.
13. Umar A, Viner JL, Anderson WF, Hawk ET. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol. 2003;26:S48-57.
14. Hinz B, Brune K. Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther. 2002;300:367-375.
15. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT. Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg. 2005;103:508-517.
16. Lee WH. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery. 1990;27:389-395; discussion 396.
17. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg. 1995;82:864-873.
18. Jensen RL, Leppla D, Rokosz N, Wurster RD. Matrigel augments xenograft transplantation of meningioma cells into athymic mice. Neurosurgery. 1998;42:130-135; discussion 135-136.
19. Ragel BT, Jensen RL. Molecular genetics of meningiomas. Neurosurg Focus. 2005;19(5):E9.
20. Akat K, Mennel HD, Kremer P, Gassler N, Bleck CK, Kartenbeck J. Molecular characterization of desmosomes in meningiomas and arachnoidal tissue. Acta Neuropathol (Berl). 2003;106:337-347.
21. Rutka JT, Giblin J, Dougherty DV, McCulloch JR, DeArmond SJ, Rosenblum ML. An ultrastructural and immunocytochemical analysis of leptomeningeal and meningioma cultures. J Neuropathol Exp Neurol. 1986;45:285-303.
22. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1589-1594.
23. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
24. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164:820-825.
25. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293-297.
26. Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schonthal AH. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther. 2004;3:55-62.
27. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 2002;531:278-284.
28. King JG Jr, Khalili K. Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen. Oncogene. 2001;20:6864-6870.
29. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60:4926-4931.
30. Fife RS, Stott B, Carr RE. Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro. Cancer Biol Ther. 2004;3:228-232.
31. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275:11397-11403.
32. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer. 2006;6:9.
33. Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 2002;62:2343-2346.
34. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004;23:63-75.
35. Srinath P, Rao PN, Knaus EE, Suresh MR. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 2003;23:3923-3928.
36. Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 2005;11:6261-6269.
37. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci. 1998;39:581-591.
38. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-lalpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem. 2002;277:50081-50086.
39. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289-293.
40. Ferrandina G, Ranelletti FO, Legge F, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res. 2003;9:4324-4331.
41. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res. 2005;11:8213-8221.
42. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431-502.
43. Couldwell WT, Weiss MH, Law RE, Hinton DR. Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas. J Neurosurg. 1995;82:461-468.
44. Karim A, Isakson P, Hubbard RC. Selective COX-2 inhibitor SC-58635: first in man administration and pharmacokinetic assessment. 8th APLAR Congress of Rheumatology. 1996;108:5-6.
45. Stempak D, Gammon J, Klein J, Koren G, Baruchel S. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther. 2002;72:490-497.
46. Frank DH, Roe DJ, Chow HH, et al. Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial. Cancer Epidemiol Biomarkers Prev. 2004;13:299-303.